12/24
12:37 am
nuvl
Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]
Low
Report
Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]
12/22
06:43 am
nuvl
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/22
06:30 am
nuvl
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/19
11:38 am
nuvl
Nuvalent (NASDAQ:NUVL) had its price target lowered by analysts at JPMorgan Chase & Co. from $147.00 to $145.00. They now have an "overweight" rating on the stock.
Low
Report
Nuvalent (NASDAQ:NUVL) had its price target lowered by analysts at JPMorgan Chase & Co. from $147.00 to $145.00. They now have an "overweight" rating on the stock.
12/17
01:07 pm
nuvl
Nuvalent (NASDAQ:NUVL) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Nuvalent (NASDAQ:NUVL) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/16
07:22 am
nuvl
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million [Yahoo! Finance]
Low
Report
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million [Yahoo! Finance]
12/10
04:01 pm
nuvl
Nuvalent Appoints Ron Squarer to Board of Directors
Low
Report
Nuvalent Appoints Ron Squarer to Board of Directors
12/9
12:27 am
nuvl
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects [Yahoo! Finance]
Low
Report
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects [Yahoo! Finance]
11/27
01:29 am
nuvl
Does Nuvalent's Recent Trial Success Justify the Stock's 36% 2025 Rally? [Yahoo! Finance]
Low
Report
Does Nuvalent's Recent Trial Success Justify the Stock's 36% 2025 Rally? [Yahoo! Finance]
11/26
06:43 am
nuvl
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
06:30 am
nuvl
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/24
04:01 pm
nuvl
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Low
Report
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
11/24
09:04 am
nuvl
Nuvalent (NASDAQ:NUVL) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Nuvalent (NASDAQ:NUVL) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
nuvl
Nuvalent (NASDAQ:NUVL) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Low
Report
Nuvalent (NASDAQ:NUVL) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/19
04:45 pm
nuvl
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC [Yahoo! Finance]
Low
Report
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC [Yahoo! Finance]
11/19
04:19 pm
nuvl
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Low
Report
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
11/18
11:50 pm
nuvl
Nuvalent Announces Pricing of Public Offering of Common Stock
Low
Report
Nuvalent Announces Pricing of Public Offering of Common Stock
11/18
01:13 pm
nuvl
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $120.00 to $135.00. They now have a "buy" rating on the stock.
Low
Report
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $120.00 to $135.00. They now have a "buy" rating on the stock.
11/18
11:04 am
nuvl
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Robert W. Baird from $112.00 to $158.00. They now have an "outperform" rating on the stock.
Low
Report
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Robert W. Baird from $112.00 to $158.00. They now have an "outperform" rating on the stock.
11/18
10:00 am
nuvl
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Guggenheim from $125.00 to $155.00. They now have a "buy" rating on the stock.
Low
Report
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Guggenheim from $125.00 to $155.00. They now have a "buy" rating on the stock.
11/18
06:38 am
nuvl
Nuvalent aiming for approval on pivotal trial data for NSCLC candidate [Yahoo! Finance]
Low
Report
Nuvalent aiming for approval on pivotal trial data for NSCLC candidate [Yahoo! Finance]
11/18
02:25 am
nuvl
Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript [Seeking Alpha]
Low
Report
Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript [Seeking Alpha]
11/17
09:32 pm
nuvl
Nuvalent (NASDAQ:NUVL) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $125.00 price target on the stock, up previously from $120.00.
Medium
Report
Nuvalent (NASDAQ:NUVL) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $125.00 price target on the stock, up previously from $120.00.
11/17
05:04 pm
nuvl
Nuvalent (NASDAQ:NUVL) was given a new $152.00 price target on by analysts at Barclays PLC.
Low
Report
Nuvalent (NASDAQ:NUVL) was given a new $152.00 price target on by analysts at Barclays PLC.
11/17
04:35 pm
nuvl
Nuvalent Announces Public Offering of Common Stock [Yahoo! Finance]
Low
Report
Nuvalent Announces Public Offering of Common Stock [Yahoo! Finance]